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surfaces.3 Most primary oral HSV 
infections are readily diagnosed based 
on clinical history, signs and symptoms 
and further laboratory investigation is 
generally not warranted.2,5 Th e majority 
of oral HSV infections are self-limiting 
with resolution usually within two weeks, 
often requiring only palliative treatment 
and supportive care as needed.3
Following primary infection, the virus 
migrates to the trigeminal nerve ganglion 
where it can remain latent indeﬁ nitely but 
may be stimulated to reactivate under a 
variety of circumstances (environmental 
triggers, stress, illness, etc.) that results 
in clinical infection.3 Th e most common 
presentation of recrudescent HSV 
infection (development of clinical lesions) 
in healthy individuals is recurrent herpes 
labialis (RHL), observed as a lesion located 
Oral and perioral (herein referred to collectively as oral) herpes simplex virus (HSV) infections represent one of the most common oral soft 
tissue disease processes encountered in 
the general population.1,2 HSV-1 serotype 
is the most common cause of orofacial 
infections, however, HSV-2 serotype 
has been implicated as a causative agent 
of these infections (and HSV-1 as the 
etiology for genital infections) due to 
sexual practices.3,4 Primary oral HSV 
infections usually occur in early childhood 
and while the majority are subclinical, 
clinical infections initially present with 
general symptoms, such as malaise, fever 
and lymphadenopathy (referred to as 
a prodrome) followed by vesicles and/
or ulcers aﬀ ecting a variety of intraoral 
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abstract  Oral and perioral herpes simplex virus (HSV) infections in healthy 
individuals oft en present with signs and symptoms that are clearly recognized by oral 
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variety of factors and several agents may be used for treatment to accelerate healing 
and decrease symptoms associated with lesions. This article will review the pertinent 
aspects of topical and systemic therapies of HSV infections for the OHCP.
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Topical antiviral agents have 
demonstrated eﬃ  cacy in accelerating the 
healing time of RHL lesions, especially 
if administered during the prodromal 
phase.6 Th e topical antiviral agents that 
are most commonly recommended to 
treat RHL include Acyclovir 5 percent 
cream, Penciclovir 1 percent cream and 
Docosanol 10 percent cream.1,2,4,13 Acyclovir 
is a nucleoside analogue of guanosine 
with a selective aﬃ  nity for thymidine 
kinase (TK), which is necessary for 
activation of acyclovir, in virus-infected 
cells.1 Acyclovir is a potent inhibitor of 
viral DNA synthesis and thus ultimately 
prevents viral replication.1 Penciclovir is an 
acyclic guanine derivative with a similar 
antiviral spectrum as acyclovir. It is also 
phosphorylated by viral TK and inhibits 
viral DNA polymerase.1,14 Penciclovir 
has approximately 1/100th the potency 
of acyclovir, but is an eﬀ ective antiviral 
agent due to its long half-life and high 
intracellular concentrations.1 Docosanol is 
a 22-carbon primary alcohol that blocks the 
virus from attaching to cells via interference 
of epithelial cell surface receptors and viral 
envelope proteins.6 Acyclovir 5 percent 
cream and Penciclovir 1 percent cream are 
available by prescription, while Docosanol 
is the only agent approved by the FDA as an 
OTC product for treatment of RHL. 
Topical formulations of foscarnet, 
cidoﬁ vir and imiquimod are generally 
reserved for treatment of RHL lesions 
that are nonresponsive to typical antiviral 
agents and are rarely used in healthy 
individuals.1,4,15 In contrast to other 
antiviral agents dependent upon viral 
TK, foscarnet and cidoﬁ vir inhibit viral 
DNA synthesis independently of this 
mechanism.1 Foscarnet has demonstrated 
eﬃ  cacy in treating acyclovir-resistant HSV 
infections, while cidofovir is generally 
reserved for both acyclovir and foscarnet-
resistant HSV infections.1,4 Imiquimod 
infections in adults for symptomatic relief 
and are often used in combination with 
systemic antiviral agents for more eﬀ ective 
management. Other topical agents that 
have been recommended for use to treat 
RHL include ice and lip compounds 
containing lanolin, cocoa butter or 
petrolatum-based products.6
Use of topical anesthetic preparations 
in the pediatric population is controversial 
due to possible increased risk of life-
threatening events.7,8 Aspiration of 
topical lidocaine in this population has 
been linked to adverse neurologic and 
cardiovascular reactions, such as seizures 
and hypotensive episodes, respectively9,10 
while ingestion of topical benzocaine 
has been associated with development 
of methemoglobinemia.8,11 In April 2011, 
the Food and Drug Administration 
(FDA) issued a safety alert regarding 
topical benzocaine products (sprays, 
liquids, gels) in association with risk of 
methemoglobinemia and recommended 
that benzocaine products not be used 
on children younger than 2 years of age, 
except under the advice and supervision 
of a health care professional.12
Preventive agents are primarily 
used for decreasing the risk of an RHL 
episode, especially if a patient is aware of 
precipitating factors, such as sun exposure. 
Evidence supports using sunscreen on 
the lips with a sun-protection factor 
(SPF) of at least 15 to decrease the risk of 
developing an episode of RHL.4,13
at the mucocutaneous junction of the 
lips (known as a fever blister or cold 
sore) (figure 1). A majority of patients 
experience prodromal symptoms preceding 
an episode of RHL, which often consists of 
pain, itching and/or burning at the site of 
lesion development.6 Recurrent intraoral 
herpes (RIH), which is observed more 
often in immunocompromised patients, 
may be diﬃ  cult to distinguish clinically 
from other oral mucosal disorders, such as 
aphthous stomatitis (figure 2). Prodromal 
symptoms preceding an episode of RIH are 
not commonly observed.6 Management of 
recurrent herpes infections is dependent 
upon frequency, severity and distribution 
of lesions and may include topical and/or 
systemic therapeutic agents. 
Topical Therapies
Topical therapies for oral HSV 
infections can be divided into palliative, 
preventive and antiviral categories. 
Palliative topical agents available over the 
counter (OTC) commonly contain the 
anesthetic benzocaine and are beneﬁ cial 
in reducing pain associated with an oral 
HSV infection. Palliative topical agents 
available by prescription, such as lidocaine 
gel 2 percent, viscous lidocaine 2 percent or 
mixtures of topical anesthetic with coating 
agents +/- diphenhyrdamine (e.g., magic 
mouthwash) may aﬀ ord patients more 
relief compared to OTC topical anesthetic 
preparations. Th ese agents may be used 
for both primary and recurrent oral HSV 
f igur e 1 .  Typical presentation of recurrent herpes labialis 
(RHL) (white arrows). (Courtesy of Martin Greenberg, DDS, 
and Thamer Musbah, BDS, University of Pennsylvania.)
figure 2 .  Recurrent intraoral herpes (RIH) of the palatal 
mucosa. (Courtesy of Martin Greenberg, DDS, University of 
Pennsylvania.)
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is a novel agent that enhances innate 
immunologic responses to viruses and 
topical formulations has shown to be 
eﬀ ective in treating resistant HSV infection 
in the setting of HIV.15 table 1 outlines the 
indications and usage recommendations 
for topical agents used for treatment of 
oral HSV infections. 
Systemic Therapies
Systemic therapies may be required 
for the treatment of primary oral HSV 
infection and treatment or prophylaxis 
of both RHL and RIH, especially in 
immunocompromised patients. Unlike 
topical agents, systemic medications enable 
greater drug exposure, rapid access to site 
of viral replication, better biocompatibilityd 
less frequent dosing and improved 
compliance. Systemic medications are 
exclusively antiviral agents and may be 
administered orally or intravenously.16,17
As noted previously, treatment of 
primary oral HSV infection is typically 
based on supportive and symptomatic 
interventions.18 However, oﬀ -label use 
of systemic antiviral medications may 
accelerate healing time of primary oral 
HSV lesions by inhibiting DNA replication 
of infected cells if commenced when 
prodromal symptoms are recognized or 
within one day of vesicle eruption.6 Oral 
acyclovir 200 mg ﬁ ve times a day or 400 mg 
three times a day for 10 days may be used in 
severe cases of primary oral HSV infection 
in adults as currently prescribed in primary 
genital infection.6 In the pediatric patient, 
treatment with oral acyclovir suspension 15 
mg/kg within three days of symptom onset 
and continued ﬁ ve times a day for one week 
was shown to accelerate healing, reduce 
viral shedding and improve oral intake.19
Contemporary antiviral medications 
such as famciclovir and valacyclovir 
may also be prescribed given their 
more convenient dosing and increased 
bioavailability.14 (table 2) Famciclovir 
(prodrug of penciclovir) is a diacetyl-6-
deoxy analogue that is rapidly absorbed 
and undergoes deacetylation in the 
gastrointestinal tract, blood and liver to 
its active form.1 Valacyclovir (prodrug of 
acyclovir) is an L-valine ester that is well 
absorbed and 99 percent converted to its 
active form in the gastrointestinal tract 
and liver.1 Th is results in a three- to ﬁ ve-
times increase in bioavailability. 14 
Systemic antiviral medications may be 
used as prophylaxis or treatment in patients 
with severe, frequent, persistent and 
unsightly outbreaks.20 Oral valacyclovir has 
been shown to be eﬀ ective and is approved 
by the FDA for the treatment of RHL.17 Oral 
acyclovir and famiciclovir are approved by 
the FDA speciﬁ cally for the treatment and 
suppression of genital herpes, but have also 
been used for RHL therapy.13,21
In the immunocompromised individual, 
such as during chemotherapy or during 
‡ Food and Drug Administration recommends benzocaine products (spray, liquid, gel) should not be used on children younger than 2 years of age, except under the advice and 
supervision of a health care professional.
* Aspiration of topical lidocaine in the pediatric population has been associated with adverse neurologic and/or cardiovascular side eﬀ ects. 
† Various combinations of agents — usually contains topical anesthetic (e.g., viscous lidocaine 2%) with coating agents (e.g., Maalox) + / - diphenhydramine.
TABLE 1
  Topical Therapies for Treatment of Oral HSV Infections
  
Category Agent Indications Recommendations
Palliative Ice, lip balms
Over-the-counter  topical anesthetic 
preparations (e.g., containing benzocaine)‡
Primary HSV infections, 
Recurrent HSL infections, 
RIH infections
As needed or per manufacturer’s 
instructions.
Topical lidocaine preparations*
(Viscous lidocaine 2%, lidocaine gel 2%)
Primary HSV infections, 
Recurrent HSL infections, 
RIH infections
Viscous lidocaine 2% - 10 ml swish 
and spit as needed for pain relief.
Lidocaine gel 2% - apply layer to 
aﬀ ected area as needed for pain relief.
Magic Mouthwash*† Primary infections, 
RIH infections
10 ml swish and spit as needed for 
pain relief.
Protective Sunscreen (SPF 15 or higher) Recurrent HSL infections As per manufacturer’s instructions.
Antiviral Acyclovir 5% cream Recurrent HSL infections Apply every two hours from the time 
of prodrome until lesions are healed.
Penciclovir 1% cream Recurrent HSL infections Apply every two hours from the time 
of prodrome until lesions are healed.
Docosanol 10% cream Recurrent HSL infections Apply every two hours from the time 
of prodrome until lesions are healed.
Topical foscarnet, cidoﬁ vir and/or 
imiquimod
Recalcitrant HSV lesions Rarely used in healthy individuals; Refer 
to appropriate health care provider for 
management with these agents.
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the use of immunosuppressive drugs, RIH 
may present as a severe outbreak.22 Oral or 
intravenous acyclovir has been shown to be 
eﬀ ective in the prevention and treatment of 
RIH in these patients.23 Similarly, valacyclovir 
and famciclovir may also be prescribed for 
the prevention and treatment of RIH in 
immunocompromised patients. table 3 
summarizes the antiviral agents available, 
their dosages and duration of use based on 
the expert recommendations from the Fourth 
World Workshop in Oral Medicine.13 Newer 
intravenous medications such as foscarnet 
and cidofovir may be necessary in acyclovir-
resistant, severely immunocompromised 
patients. Th ese medications are highly 
nephrotoxic and should be used with caution.21
Conclusions
Th ere is a variety of treatment 
modalities for oral HSV infections. OHCPs 
must be cognizant of the advantages and 
limitations of both topical and systemic 
therapies for this condition. It is imperative 
for OHCPs to determine the appropriate 
agents for treatment in the context of the 
patient’s disease presentation and overall 
medical status. 
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* Food and Drug Administration treatment recommendations for genital herpes
+ Recommendations from the Center for Disease Control and Prevention for genital herpes
TABLE 2
  Systemic Antiviral Medications for the Treatment of Primary Herpes 
Simplex Virus Infection
Acyclovir  Valacyclovir Famciclovir
Dose 200 mg * 400 mg + 1000 mg * 250 mg +
Frequency 5x/day 3x/day 2x/day 3x/day
Duration 7–10 days 7–10 days 7–10 days 7–10 days
Adapted and modiﬁ ed from Woo SB, Challacombe SJ. “Management of recurrent oral herpes simplex infections.” 
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103 (suppl 1): S12.e1-S12.e18.
* Duration of the prophylaxis is based on the extent and frequency of exposure to triggers of RHL episodes, such as 
sunlight, dental treatment, etc. 
TABLE 3
  Systemic Therapies for Treatment of Oral HSV Infections
  
Indication Therapy
Treatment of RHL in the 
immunocompetent host
Oral acyclovir 400 mg three times a day for ﬁ ve to seven days
Oral valacyclovir 500 mg to 2000 mg twice a day for one day
Oral famciclovir 500 mg two to three times a day for three days
Prophylaxis of RHL in the 
immunocompetent host *
Oral acyclovir 400 mg two to three times a day
Oral valacyclovir 500 mg to 2000 mg twice a day
Treatment of recurrent 
HSV infections in the 
immunocompromised host 
Oral acyclovir 400 mg three times a day for 10 days or longer 
as necessary
Oral valacyclovir 500–1000 mg twice a day for 10 days or longer 
as necessary
Oral famciclovir 500 mg twice a day for up to one year
Prophylaxis of recurrent 
HSV infections in the 
immunocompromised host
Oral acyclovir 400–800 mg three times a day
Oral valacyclovir 500–1000 mg twice a day
Oral famciclovir 500–1000 mg twice a day
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